BridgeMD
Tests treatment safety and results for Post-inflammatory Hyperpigmentation
Official title A Clinical Study to Evaluate the Efficacy in Improving Dark Spots After 8 Weeks of Use of Facial Sunscreens in Adult Participants
ClinicalTrials.gov ID: NCT07679945
What this study is testing
- What it's testing
- The study aims to evaluate the efficacy of a facial sunscreen under two experimental conditions-untinted and tinted-in improving facial spots (melasma and solar lentigines/post-inflammatory hyperpigmentation) after 8 weeks of product use under normal conditions by adult participants.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older. Healthy volunteers may be eligible.
You may be able to join if
- Able to understand and follow study instructions
- Fitzpatrick skin types I-VI
- Presence of facial hyperpigmentation, such as:
- Mild to moderate melasma, or
- Visible dark spots (e.g., solar lentigines or post-inflammatory hyperpigmentation)
You likely can't join if
- Known sensitivity or allergy to cosmetic or skincare products
- Skin conditions or lesions in the study area that could interfere with evaluation (e.g., active dermatitis, infections, significant irritation, or...
- Use of medications or products that may interfere with study evaluations
- Recent cosmetic or dermatological procedures in the study area (e.g., chemical peels, laser treatments, invasive procedures)
- Excessive sun exposure or use of tanning beds immediately prior to or during the study
- Pregnancy or intention to become pregnant during the study
See the full eligibility criteria
- Able to understand and follow study instructions
- Fitzpatrick skin types I-VI
- Presence of facial hyperpigmentation, such as:
- Mild to moderate melasma, or
- Visible dark spots (e.g., solar lentigines or post-inflammatory hyperpigmentation)
- Willing to comply with study procedures and product use
- For people in applicable groups: willing to use assigned sunscreen product
- Known sensitivity or allergy to cosmetic or skincare products
- Skin conditions or lesions in the study area that could interfere with evaluation (e.g., active dermatitis, infections, significant irritation, or extensive scarring)
- Use of medications or products that may interfere with study evaluations
- Recent cosmetic or dermatological procedures in the study area (e.g., chemical peels, laser treatments, invasive procedures)
- Excessive sun exposure or use of tanning beds immediately prior to or during the study
- Pregnancy or intention to become pregnant during the study
- Participation in another clinical study within a recent period
- Any condition or situation that, in the investigator's judgment, may interfere with study participation or evaluation of results
The study team makes the final eligibility decision.
Where it's taking place
- Campinas, São Paulo, Brazil
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Campinas, São Paulo, Brazil. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.